Protagen Protein Services and BioAnalytix Merge
Create Global Analytic Service Partner for Biopharmaceuticals
Protagen Protein Services GmbH (PPS), a full-service contract research organization (CRO) in protein analytics and BioAnalytix Inc., a Cambridge (MA)-based specialized provider of advanced analytics in biologic development announced a merger that will transform the combined company into a leading global analytic CRO. The announcement creates a best-in-class partner for the biopharmaceutical industry worldwide to benefit from the most advanced, integrated and complete analytic services capabilities and platforms in biopharmaceutical development, from clone selection through drug approval to commercialization.
Protagen Protein Services and BioAnalytix Merge to Create Global Analytic Service Partner for Biopharmaceuticals
Protagen Protein Services GmbH
In working together with its pharmaceutical partners, the PPS and BioAnalytix teams generate analytic data packages and provide scientific, technical and regulatory support to advance, de-risk and accelerate all stages of biopharmaceutical development including biosimilar development at highest quality from clone through clinic.
Martin Blüggel, Founder and CEO of PPS, stated “Both companies have shared a similar vision, entrepreneurial agility and heritage of excellence in supporting leading pharmaceutical companies with high-end analytics and strategic solutions through development. We are fascinated to serve our pharma partners more directly in the FDA and EMEA territories, and continue our expansion in capacities and capabilities now including BioAnalytix’s innovative areas such as HDX-MS and in-vivo CQA Mapping.”
Kirtland Poss, Founder and CEO of BioAnalytix added, “We’re thrilled about the combination of the companies and their analytic offerings. The broader platforms will enable us to provide a significantly greater range of analytic data packages and regulatory support here in the US as we strengthen our focus on delivering analytic excellence in advancing, de-risking and accelerating all stages of biotherapeutic development with our pharma partners.”
By combining analytic platforms, programs and highly experienced teams based both in US and in Europe, PPS and BioAnalytix will work directly and more broadly with leading biopharmaceutical companies in designing, generating and delivering integrated analytical data packages, and strategic support along the full development continuum, from developabilityand lead optimization, clone selection and process development, extended characterization and comparability, stability testing for control strategy design and CMC filings through commercialization and full GMP testing of commercial products.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.